A Study of the Pharmacokinetic Profile of Low-Dose Hepatitis B Immune Globulin in Long-Term Liver Transplant Recipients for Chronic Hepatitis B Infection

American Journal of Transplantation

Volumn 1, Issue 1, 2001, Pages 51-54

  Partovi, Nilufar ^a,b   Guy, Michelle W ^a   Ensom, Mary H H ^b   Noble, Michael A ^b   Yoshida, Eric M ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HBIG; Hepatitis B; Immune globulin; Liver transplantation; Pharmacokinetic

Indexed keywords

HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; VIRUS DNA;

AREA UNDER THE CURVE; ARTICLE; BLOOD; HALF LIFE TIME; HEPATITIS B; HUMAN; IMMUNOLOGY; LIVER TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PASSIVE IMMUNIZATION; TIME;

AREA UNDER CURVE; DNA, VIRAL; HALF-LIFE; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0035342093     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2001.010110.x     Document Type: Article

References (14)

1. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
2. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
3. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
4. Al-Hemsi B, McGory RW, Shepard B et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996; 10: 668-675.
5. Lai CL, Chien RN, Leung NWY, Chang TT et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
6. Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456-1462.
7. Grellier L, Multimer D, Ahmed M et al. Lamivudine prophylaxis against re-infection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
8. Yoshida EM, Ma MM, Davis JE et al. Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up. Can J Gastroenterol 1998; 12: 125-129.
9. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B infection in the liver transplant recipient. Gut 2000; 46: 107-113.
10. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
11. Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplant Surg 1999; 5: 520-525.
12. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 1999; 5: 491-496.
13. Yoshida EM, Sherlock CH. Assessing virologic efficacy of combination lamivudine and low-dose hepatitis B immune globulin posttransplantation with the Ultrasensitive Digene Hybrid Capture II Assay [letter]. Liver Transplant 2000; 6: 386.
14. Burbach GJ, Bienzle U, Neuhaus R et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B. reinfection after orthotopic liver transplantation. Transplantation 1997; 63: 478-480.